Search research articles
Contact Us
Filters
Showing results (31-40 of 75) with videos related to
Page
of 8
Sort By:
Clinical Genitourinary Cancer
|
October 24, 2021
Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma
Luigi Cerbone, Vincenzo Di Nunno, Lucia Carril Ajuria, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
July 29, 2022
Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
Emeline Colomba, Carolina Alves Costa Silva, Gwénaël Le Teuff, et al.
Therapeutic Advances in Medical Oncology
|
October 2, 2025
The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond
Alice Bernard-Tessier, Natacha Naoun, Solenn Barraud, et al.
The Oncologist
|
February 8, 2021
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma
Elie Rassy, Luigi Cerbone, Edouard Auclin, et al.
Bulletin Du Cancer
|
April 11, 2025
[Intercontinental Multidisciplinary Oncology Videoconferencing between the South Pacific and the French mainland: Reasons for medical evacuation after more than 2000 cases of cancers discussed]
Charles Honoré, Nicolas Epaillard, Arthur Geraud, et al.
Scientific Reports
|
August 19, 2017
Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma
Ronan Flippot, Roger Mouawad, Jean-Philippe Spano, et al.
Journal for Immunotherapy of Cancer
|
April 3, 2020
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
Pier Vitale Nuzzo, Gregory R Pond, Sarah Abou Alaiwi, et al.
Bulletin Du Cancer
|
September 2, 2023
Real-world dostarlimab use in advanced/recurrent endometrial cancer in France
Manuel Rodrigues, Lauriane Eberst, Philippe Follana, et al.
Clinical Genitourinary Cancer
|
August 27, 2023
Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN
Guillemette Guilhem-Ducléon, Cécile Dalban, Sylvie Negrier, et al.
Journal for Immunotherapy of Cancer
|
April 17, 2024
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
Ronan Flippot, Marcus Teixeira, Macarena Rey-Cardenas, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 75) with videos related to
Sort By:
Page
of 8
Clinical Genitourinary Cancer
|
October 24, 2021
Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma
Luigi Cerbone, Vincenzo Di Nunno, Lucia Carril Ajuria, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
July 29, 2022
Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
Emeline Colomba, Carolina Alves Costa Silva, Gwénaël Le Teuff, et al.
Therapeutic Advances in Medical Oncology
|
October 2, 2025
The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond
Alice Bernard-Tessier, Natacha Naoun, Solenn Barraud, et al.
The Oncologist
|
February 8, 2021
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma
Elie Rassy, Luigi Cerbone, Edouard Auclin, et al.
Bulletin Du Cancer
|
April 11, 2025
[Intercontinental Multidisciplinary Oncology Videoconferencing between the South Pacific and the French mainland: Reasons for medical evacuation after more than 2000 cases of cancers discussed]
Charles Honoré, Nicolas Epaillard, Arthur Geraud, et al.
Scientific Reports
|
August 19, 2017
Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma
Ronan Flippot, Roger Mouawad, Jean-Philippe Spano, et al.
Journal for Immunotherapy of Cancer
|
April 3, 2020
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
Pier Vitale Nuzzo, Gregory R Pond, Sarah Abou Alaiwi, et al.
Bulletin Du Cancer
|
September 2, 2023
Real-world dostarlimab use in advanced/recurrent endometrial cancer in France
Manuel Rodrigues, Lauriane Eberst, Philippe Follana, et al.
Clinical Genitourinary Cancer
|
August 27, 2023
Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN
Guillemette Guilhem-Ducléon, Cécile Dalban, Sylvie Negrier, et al.
Journal for Immunotherapy of Cancer
|
April 17, 2024
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
Ronan Flippot, Marcus Teixeira, Macarena Rey-Cardenas, et al.
Page
of 8